

Date: 12th February, 2021

To,
Listing Department,
BSE Limited,
Floor 25, PJ Tower
Dalal Street,
Mumbai – 400 001

Script Code: 540359

Sub.: Outcome of the proceedings of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 4th February, 2021 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved:

- i. Unaudited Financial Results for quarter and Nine months ended 31st December, 2020. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and nine months ended 31st December, 2020.

We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter and nine months ended 31st December, 2020 and Board has also taken on record their Limited Review Report on said Results.

- ii. Tabled and took note of the resignation tendered by Mr. Alkesh M. Gopani from the post of Managing Director as well as Director of the Company.
- iii. Tabled and took note of the resignation tendered by Mr. Vipul M. Gopani from the post of Director of the Company.
- iv. Upon the recommendation of Nomination and Remuneration Committee and subject to approval of shareholders in ensuing General Meeting Board has re-appointed Mrs. Asha S. Daftary as an independent Director of the company for a period of 5 years.
- v. Upon the recommendation of Nomination and Remuneration Committee and subject to approval of shareholders in ensuing General Meeting Board has re-appointed Mr. Pramay A. Chhatra as an independent Director of the company for a period of 5 years.

The meeting was commenced at 4.30 pm and was concluded at 5:45 pm.



Since publications are closed on 14th February, 2021, hence our results can only be published on its next day i.e. 15th February 2021.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

Yash Jain

Yash J. Vora
Company Secretary



Encl: As above

Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2020							
(in Rs.)							
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	104508255	60892852	69384878	188132432	165656070	209341081
II.	Other income	232691	306613	91943	654568	476941	977787
III.	Total Income (I+II)	104740946	61199465	69476821	188787000	166133011	210318868
IV.	Expenses						
	(a) Cost of materials consumed	54127141	23671263	33830775	102576659	82364743	97936820
	(b) Purchase of stock-in-trade	0	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-84543	8556428	2577986	-8081735	4149121	14722662
	(d) Employee benefits expense	12567329	8156031	7372508	28969366	22351538	29139115
	(e) Finance Costs	1154942	916846	116779	2985356	360875	1273690
	(f) Depreciation and amortisation expense	5174121	4857728	2170283	14400512	6359296	10071526
	(g) Other expenses*	16433528	9873220	13239244	37360648	37425543	49868688
	Total expenses (IV)	89372518	56031516	59307575	178210806	153011116	203012501
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	15368428	5167949	10169246	10576194	13121895	7306367
VI.	Exceptional Items	0	0	0	0	0	0
VII.	Profit/ (Loss) before tax (V-VI)	15368428	5167949	10169246	10576194	13121895	7306367
VIII.	Tax expense:				0		
	(1) Current tax	0	0	0	0	0	1500000
	(2) Deferred tax	0	0	0	0	0	1,519,577
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	15368428	5167949	10169246	10576194	13121895	4286790
X.	Profit/(loss) from discontinued operations						
XI.	Tax expense of discontinued operations	0	0	0	0	0	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XIII.	Profit (Loss) for the period (IX+XII)	15368428	5167949	10169246	10576194	13121895	4286790
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	15368428	5167949	10169246	10576194	13121895	4286790
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000	37413000
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	4.11	1.38	2.72	2.83	3.51	1.15
	(b) Diluted						

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12.02.2021
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2020
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2020, in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED

Alkesh Gosalia

Alkesh Gosalia
Managing Director (Finance and Operations)



Place Hadamtala (Rajkot)
Date: 12.02.2021

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and nine months ended on **31st December 2020** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **12th February 2021**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there



Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr. Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G. Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 12.02.2021



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B. Shah".

MALAY B SHAH

Partner

M. No. 159526

UDIN : 21159526AAAAAC6279

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com